UDCA for Cholelithiasis
UDCA is indicated for dissolution of small (<20mm), radiolucent, non-calcified cholesterol gallstones in patients with a functioning gallbladder who are poor surgical candidates, at a dose of 8-10 mg/kg/day divided in 2-3 doses, with treatment duration of 6-24 months and ultrasound monitoring every 6 months. 1
Indications for UDCA Treatment
UDCA should be used specifically for:
- Radiolucent, non-calcified gallstones less than 20mm in greatest diameter
- Functioning gallbladder (confirmed on imaging)
- Patients who are poor surgical candidates due to:
- Systemic disease
- Advanced age
- Idiosyncratic reaction to general anesthesia
- Patient refusal of surgery 1
Critical caveat: UDCA is NOT appropriate for calcified stones, non-functioning gallbladder, or stones >20mm, as efficacy drops dramatically in these scenarios.
Dosing Protocol
For Gallstone Dissolution:
- Standard dose: 8-10 mg/kg/day divided in 2-3 doses 1
- Higher efficacy demonstrated with 600 mg/day in clinical trials 2, 3
- Treatment duration: typically 6-24 months (safety beyond 24 months not established) 1
For Gallstone Prevention (Post-Bariatric Surgery):
- 600 mg/day (300 mg twice daily) 1
- Duration: 6 months post-operatively 4, 5, 6
- This dose reduces gallstone formation from 38% to 8% in post-bariatric patients 4
Monitoring Requirements
Structured monitoring algorithm:
- Baseline: Confirm radiolucent stones <20mm on ultrasound with functioning gallbladder
- 6 months: First ultrasound reassessment
- If partial/complete dissolution → continue therapy
- If no change → reassess candidacy
- 12 months: Critical decision point
- If no partial dissolution by 12 months → discontinue therapy (likelihood of success greatly reduced) 1
- If dissolution progressing → continue to completion
- Upon apparent complete dissolution: Confirm with repeat ultrasound in 1-3 months 1
Efficacy Expectations
Response rates vary by stone characteristics:
- Optimal candidates (non-calcified, <15mm, floating stones): 83% efficacy 2
- Small stones (<5mm): Higher dissolution rates 7
- Larger stones (15-20mm): Significantly lower efficacy
- Overall dissolution rate: 23-34% in unselected patients 2, 7
Time to dissolution:
- 74% of successful dissolutions occur within first 6 months with UDCA 3
- UDCA demonstrates faster dissolution than chenodeoxycholic acid at equivalent doses 3
Comparative Advantage
UDCA is superior to chenodeoxycholic acid (CDCA) because:
- Equally effective at low and high doses (unlike CDCA which requires higher doses) 3
- No diarrhea or hepatotoxicity (unlike CDCA which causes both) 2, 3
- Faster dissolution in first 6 months 3
Special Populations
Pregnancy:
- FDA Category B (low risk) 8
- Can be administered during second or third trimesters when symptomatic 8
- Particularly effective for intrahepatic cholestasis of pregnancy at 10-15 mg/kg/day 9
Post-Bariatric Surgery:
- Strong recommendation for prophylaxis: 500-600 mg/day for 6 months 4, 5, 6
- Reduces symptomatic gallstone disease by 70% (RR 0.30) 4
- Should be implemented as standard postoperative care 5
Important Limitations
UDCA does NOT work for:
- Calcified stones (radiopaque on imaging)
- Non-functioning gallbladder
- Stones >20mm diameter
- Acute cholecystitis or cholangitis (requires urgent intervention) 8
Common pitfall: Do not use UDCA with cholestyramine simultaneously—space doses minimum 4 hours apart to prevent binding and loss of efficacy 8
When to Abandon Medical Therapy
Discontinue UDCA if:
- No partial dissolution by 12 months 1
- Development of complications (cholecystitis, cholangitis, pancreatitis)
- Stone calcification develops
- Patient becomes surgical candidate
Note: Most clinicians remain uncertain about UDCA benefit for symptomatic gallstones, with 95% stating they would use it only if RCT evidence demonstrated benefit 10. Current evidence is heterogeneous but generally favorable for biliary pain reduction 10.